{
  "nctId": "NCT03126370",
  "briefTitle": "Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)",
  "officialTitle": "Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.",
  "protocolDocument": {
    "nctId": "NCT03126370",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2018-03-29",
    "uploadDate": "2020-09-30T17:42",
    "size": 519491,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03126370/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE4"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 10,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2018-01-08",
    "completionDate": "2019-10-01",
    "primaryCompletionDate": "2019-07-12",
    "firstSubmitDate": "2017-04-19",
    "firstPostDate": "2017-04-24"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Between 18-70 years of age\n* Have been taking TDF and a ritonavir- or cobicistat-boosted protease inhibitor as part of standard care for treatment of HIV\n\nExclusion Criteria:\n\n* eGFR \\< 30 mL/min\n* Pregnant or planning pregnancy\n* Breastfeeding\n* Any medical, social, or mental-health issue(s) that, in the opinion of the investigators, could interfere with study participation or the study outcomes\n* Signs or symptoms of decompensated liver disease\n* Hepatitis B infection\n* Medications that may cause unwanted drug interactions with ledipasvir/sofosbuvir or emtricitabine/tenofovir alafenamide\n* Unwillingness or inability to comply with study procedures\n* Chronic hepatitis C infection",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "70 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change From Week 12 Plasma Tenofovir Area Under the Plasma Concentration vs. Time Curve From Time 0 to 24 Hours (AUC0-24) at 24 and 28 Weeks",
        "description": "Compare plasma tenofovir AUC0-24 between TAF with boosted PI vs. TDF with boosted PI (Phase 2 vs. 1), and between TAF with boosted PI and LDV/SOF vs. TDF with boosted PI (Phase 3 vs. 1)",
        "timeFrame": "12 weeks and 24 weeks and 28 weeks"
      },
      {
        "measure": "Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs) at 24 and 28 Weeks",
        "description": "Compare tenofovir-diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1).",
        "timeFrame": "12 weeks, and 24 weeks and 28 weeks"
      }
    ],
    "secondary": [
      {
        "measure": "Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS)",
        "description": "Compare tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1)",
        "timeFrame": "12 weeks and 24 and 28 weeks"
      },
      {
        "measure": "Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: eGFR",
        "description": "Change in estimated glomerular filtration rate (eGFR)",
        "timeFrame": "12 weeks, 24 weeks, and 28 weeks"
      },
      {
        "measure": "Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: UPCR",
        "description": "Change in estimated glomerular filtration rate (eGFR) and renal biomarkers: Urine protein to creatinine ratio (UPCR)",
        "timeFrame": "12 weeks, 24 weeks, and 28 weeks"
      },
      {
        "measure": "Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: B2M/Cr Ratio, and RBP/Cr Ratio",
        "description": "Change in renal biomarkers: urinary beta-2 microglobulin (B2M)/creatinine (Cr) ratio, and urinary retinol binding protein (RBP)/Cr ratio",
        "timeFrame": "12 weeks, 24 weeks, and 28 weeks"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 4,
      "otherCount": 0,
      "totalCount": 6
    },
    "studyDesign": {
      "phases": [
        "PHASE4"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 44,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:23.686Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}